{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Certolizumab+pegol+%28CZP%29&page=2", "query": { "intervention": "Certolizumab pegol (CZP)", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 85, "total_pages": 9, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Certolizumab+pegol+%28CZP%29&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Certolizumab+pegol+%28CZP%29&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-09T18:54:42.067Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03546335", "title": "Zr-89 Cimzia PET Imaging Rheumatoid Arthritis", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "89Zr-DFO-CZP", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Robert Flavell, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2018-10-01", "completion_date": "2029-03-31", "has_results": false, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-10-09T18:54:42.067Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03546335" }, { "nct_id": "NCT02451748", "title": "IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Lab Work", "type": "OTHER" }, { "name": "Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg)", "type": "DRUG" }, { "name": "Certolizumab pegol (CDP870, tradename Cimzia)", "type": "DRUG" }, { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Sulfasalazine", "type": "DRUG" }, { "name": "Medrol", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Triamcinolone", "type": "DRUG" }, { "name": "Naproxen", "type": "DRUG" }, { "name": "Leflunomide", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "humira", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "University of Illinois at Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2015-08", "completion_date": "2017-12", "has_results": true, "last_update_posted_date": "2024-07-10", "last_synced_at": "2026-10-09T18:54:42.067Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02451748" }, { "nct_id": "NCT02353780", "title": "Mechanistic Studies of B- and T-Cell Function in RA Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Rheumatoid Arthritis (RA)" ], "interventions": [ { "name": "TNF Antagonist (enbrel, humire, remicade, cimzia, symponi)", "type": "DRUG" }, { "name": "Abatacept", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dr. Larry W. Moreland", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 10, "start_date": "2015-03", "completion_date": "2018-11-30", "has_results": true, "last_update_posted_date": "2020-10-01", "last_synced_at": "2026-10-09T18:54:42.067Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02353780" }, { "nct_id": "NCT07352566", "title": "Utilization of a Microdevice for Psoriasis and Atopic Dermatitis", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Psoriasis", "Atopic Dermatitis" ], "interventions": [ { "name": "In situ cutaneous microdevice", "type": "DEVICE" }, { "name": "Triamcinolone", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Calcipotriene", "type": "DRUG" }, { "name": "Tapinarof", "type": "DRUG" }, { "name": "Crisaborole", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" }, { "name": "Etanercept", "type": "DRUG" }, { "name": "Certolizumab", "type": "DRUG" }, { "name": "Infliximab", "type": "DRUG" }, { "name": "Secukinumab", "type": "DRUG" }, { "name": "Ixekizumab", "type": "DRUG" }, { "name": "Apremilast", "type": "DRUG" }, { "name": "Risankizumab", "type": "DRUG" }, { "name": "Ustekinumab", "type": "DRUG" }, { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Mycophenolate", "type": "DRUG" }, { "name": "Azathioprine", "type": "DRUG" }, { "name": "Chloroquine", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Tofacitinib", "type": "DRUG" }, { "name": "Deucravacitinib", "type": "DRUG" }, { "name": "Dupilumab", "type": "DRUG" }, { "name": "Tralokinumab", "type": "DRUG" }, { "name": "Guselkumab", "type": "DRUG" }, { "name": "Tildrakizumab", "type": "DRUG" }, { "name": "Baractinib", "type": "DRUG" }, { "name": "Abrocitinib", "type": "DRUG" }, { "name": "Upadacitinib", "type": "DRUG" }, { "name": "Lebrikizumab", "type": "DRUG" }, { "name": "Nemolizumab", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Bimekizumab", "type": "DRUG" }, { "name": "Roflumilast", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2026-08-01", "completion_date": "2030-06-01", "has_results": false, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-10-09T18:54:42.067Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07352566" }, { "nct_id": "NCT00580840", "title": "Dosing Flexibility Study in Patients With Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Certolizumab pegol", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "UCB Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 333, "start_date": "2007-12", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2018-08-02", "last_synced_at": "2026-10-09T18:54:42.067Z", "location_count": 50, "location_summary": "Huntsville, Alabama • Montgomery, Alabama • Gilbert, Arizona + 47 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Paradise Valley", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00580840" }, { "nct_id": "NCT01292265", "title": "A 12 Week Study to Assess Changes in Joint Inflammation Using Ultrasonography in Patients With Rheumatoid Arthritis (RA)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Certolizumab Pegol", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "UCB Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2011-02", "completion_date": "2012-01", "has_results": true, "last_update_posted_date": "2018-08-01", "last_synced_at": "2026-10-09T18:54:42.067Z", "location_count": 6, "location_summary": "Los Angeles, California • Walnut Creek, California • Wheaton, Maryland + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Walnut Creek", "state": "California" }, { "city": "Wheaton", "state": "Maryland" }, { "city": "Voorhees Township", "state": "New Jersey" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01292265" }, { "nct_id": "NCT03152058", "title": "IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "High Risk Pregnancy", "Pregnancy Complications", "Antiphospholipid Syndrome in Pregnancy", "Lupus Anticoagulant Disorder" ], "interventions": [ { "name": "Certolizumab Pegol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "David Ware Branch", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "FEMALE", "summary": "18 Years to 40 Years · Female only" }, "enrollment_count": 55, "start_date": "2017-05-17", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-04-01", "last_synced_at": "2026-10-09T18:54:42.067Z", "location_count": 2, "location_summary": "New York, New York • Salt Lake City, Utah", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT03152058" }, { "nct_id": "NCT01087788", "title": "Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Arthritis, Psoriatic" ], "interventions": [ { "name": "CZP 200 mg Q2W", "type": "BIOLOGICAL" }, { "name": "CZP 400 mg Q4W", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "UCB BIOSCIENCES GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 409, "start_date": "2010-03", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2018-08-01", "last_synced_at": "2026-10-09T18:54:42.067Z", "location_count": 27, "location_summary": "Birmingham, Alabama • Tuscaloosa, Alabama • Peoria, Arizona + 24 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Palm Desert", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01087788" }, { "nct_id": "NCT00844285", "title": "SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Crohn's Disease" ], "interventions": [ { "name": "Cimzia", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UCB BIOSCIENCES, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3072, "start_date": "2009-01-30", "completion_date": "2020-08-21", "has_results": true, "last_update_posted_date": "2023-05-06", "last_synced_at": "2026-10-09T18:54:42.067Z", "location_count": 197, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 157 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00844285" }, { "nct_id": "NCT01147341", "title": "Can TNF-Alpha Incomplete Secondary Responders Attain a Safe and Efficacious Response Switching to Cimzia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Cimzia", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Michael Schiff, MD", "sponsor_class": "INDIV", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 37, "start_date": "2010-07", "completion_date": "2012-01", "has_results": true, "last_update_posted_date": "2014-06-09", "last_synced_at": "2026-10-09T18:54:42.067Z", "location_count": 12, "location_summary": "Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 9 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Lincoln", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01147341" } ] }